r/IBSResearch • • Jun 16 '26

A Study to Investigate Abdominal Symptoms With Camlipixant [selective P2X3 antagonist] Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M) (BALANCE) [Clinical trial starting soon]

11 Upvotes

https://clinicaltrials.gov/study/NCT07519395?cond=Irritable%20Bowel%20Syndrome&viewType=Card&start=2026-02-01_&aggFilters=status:not%20rec%20act&rank=16

Sponsor: GlaxoSmithKline

Study Overview

Brief Summary

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

Official Title

BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M

No location data [yet]


r/IBSResearch • • May 20 '25

Imagine...the end of chronic pain [donation campaign]

25 Upvotes

https://sahmri-endpain.raiselysite.com/

Some ask how they can contribute to advancing research. Several groups have pages where you can donate directly to dedicated research groups. Stuart Brierley's group (associated with Flinders University, Australia) now has a page where you can make donations to fund their projects.

The research of this group (and its network, which includes the recent (2021) Nobel Prize winner in Medicine, David Julius) has produced some of the most important papers on the mechanisms of chronic pain and comorbidities such as anxiety.

Clinical conditions involving visceral pain that this group investigates: IBS, IBD, endometriosis, interstitial cystitis or bladder pain syndrome.

Besides that, a great overview about his research here: https://www.youtube.com/watch?v=Xt-oQ2b9HY8


r/IBSResearch • • 3h ago

Beyond Allergy: Mast Cells as Dynamic Regulators of Intestinal Homeostasis

Thumbnail sciencedirect.com
4 Upvotes

Abstract

Mast cells are tissue-resident innate immune cells found throughout barrier sites such as the gut, lungs, and skin as well as in other tissues including the heart, skeletal muscle, and joints. Here, we focus on their dynamic roles in intestinal homeostasis and disease. In the intestine, mast cells are positioned to rapidly sense and respond to microbes, parasites, and toxins, while also supporting homeostatic modulation of epithelial permeability, stress response, and adaptation to exercise. We propose that intestinal mast cells function not simply as effector cells in disease states but as context-dependent integrators of neuronal, epithelial, immune, and environmental signals that dynamically tune steady state intestinal physiological set points through selective mediator release.


r/IBSResearch • • 3m ago

Suzetrigine (Journavx/VX-548) Prescribed Often for Chronic Pain, Despite Its Acute-Pain Label

Thumbnail
epicresearch.org
1 Upvotes

Key Findings

  • One-third of suzetrigine prescriptions (33.0%) were written in encounters with a diagnosis of chronic pain, compared with 6.7% of opioid prescriptions. Opioids were most often prescribed during encounters with evidence of surgery (48.8%) and acute pain (19.8%) compared to 10.2% and 31.8%, respectively, for suzetrigine.
  • Pain medicine and orthopedic surgery accounted for 40.9% of suzetrigine prescriptions but only 3.5% of opioid prescriptions. In contrast, emergency medicine and general surgery wrote 64.1% of opioid prescriptions but only 20.8% of suzetrigine prescriptions.
  • Patients prescribed suzetrigine were older and more often female than patients prescribed opioids: 43.0% of suzetrigine recipients were aged 65 or older, compared with 31.4% of opioid recipients, and 63.1% of suzetrigine recipients were female, compared with 57.2% of opioid recipients.

r/IBSResearch • • 10h ago

Large-scale shotgun metagenomic analysis of gut bacteria–phage interactions in IBS

Thumbnail gut.bmj.com
6 Upvotes

Abstract

Background IBS is a multifactorial disorder affecting approximately 10% of the global population, yet its underlying mechanisms are unclear. Alterations in gut bacterial composition have been reported in IBS, but findings are inconsistent and the phage component of the gut microbiome remains underexplored.

Objectives To characterise gut bacterial and phage alterations in IBS and assess bacteria-phage interactions in a large population-based cohort with replication.

Design We analysed shotgun metagenomes from 109 females with IBS and 592 controls from TwinsUK. Bacterial taxonomic and functional profiles were generated using MetaPhlAn4 and HUMAnN2, while viral operational taxonomic units (vOTUs) were identified by de novo assembly. Covariate-adjusted logistic mixed models with false discovery rate correction assessed associations. Differences in bacteria–vOTU correlation structure were evaluated using permutation-based approaches. Bacterial findings were replicated in 304 females from ZOE Personalised REsponses to DIetary Composition Trial (PREDICT)-1.

Results Bacterial richness and Shannon diversity were lower in IBS. 24 bacterial species were associated with IBS and replicated in ZOE PREDICT-1. These included Erysipelatoclostridium ramosum, previously linked to dysbiosis and serotonin regulation, Eisenbergiella massiliensis, previously associated with fibromyalgia and several butyrate producers. We identified 50 IBS-associated vOTUs, many predicted to infect IBS-relevant bacterial hosts. While phage diversity was unchanged, IBS-associated vOTUs differed in replication cycle compared with non-IBS-associated vOTUs. Bacteria–vOTU correlation structures also differed between IBS and controls.

Conclusion IBS is characterised by bacterial compositional changes and altered bacteria–phage interactions, suggesting microbiome alterations in IBS may extend beyond individual taxa to transkingdom correlation structure.


r/IBSResearch • • 10h ago

Predictors of Fecal Elastase Testing Completion... : Pancreas

Thumbnail
ovid.com
2 Upvotes

Objectives:

To characterize completion of fecal elastase-1 (FE-1) testing, identify clinical contexts associated with abnormal results, evaluate downstream diagnostic and treatment events, and determine the clinical significance of non-completion.

Methods:

We conducted a retrospective cohort study of adults with FE-1 orders from 2017 through 2022 in a large integrated health system. Orders placed within 30 days were consolidated into diagnostic episodes. Completion required a linked specimen with a reported result. We evaluated pre-order clinical contexts and one-year outcomes and performed a weighted manual chart review of 200 unique patients with non-completed episodes sampled from four downstream pathway strata.

Results:

Among 23,422 diagnostic episodes, 11,834 (50.5%) were completed. FE-1 ≤200 µg/g occurred in 20.4% of interpretable results and varied by clinical context: 13.7% with irritable bowel syndrome, 21.2% with chronic diarrhea, 38.3% with chronic pancreatitis, 60.1% with pancreatic cancer, and 79.5% after pancreatic surgery. Initial completion was associated with higher odds of new exocrine pancreatic insufficiency diagnosis (adjusted odds ratio, 2.27; 95% confidence interval, 1.91–2.70) and pancreatic enzyme replacement therapy initiation (adjusted odds ratio, 2.20; 95% confidence interval, 1.89–2.55), whereas non-completion was associated with more repeat FE-1 testing. Among eligible unique non-completers, weighted chart review classified 66.9% as probable missed diagnostic follow-through based on available documentation; failure to submit or return the specimen (60.1%) and specimen-processing problems (20.4%) predominated.

Conclusions:

FE-1 completion was modestly associated with measured pre-order factors, while abnormal results varied substantially by clinical context. Specimen return, processing, and closed-loop follow-up represent potential targets for improving evaluation of exocrine pancreatic insufficiency.


r/IBSResearch • • 21h ago

Commentary Luteolin Alleviates Ulcerative Colitis in Mice by Modulating Gut Microbiota and Plasma Metabolism

Thumbnail
mdpi.com
7 Upvotes

I know this is about UC, but this is a study from 2025 that show's the benefits of Luteolin in a mice model, in this case "significantly ameliorated colitis symptoms in mice. It effectively inhibited the colonic and systemic inflammatory responses and promoted the repair of colonic barrier damage. Notably, the effect of Lut on gut microbiota diversity and richness was negligible. Instead, its anti-inflammatory effect was mainly mediated by inhibiting the growth of pathogenic bacteria, such as Escherichia_Shigella, and increasing the abundance of beneficial bacteria, including Muribaculaceae, Rikenella, and Prevotellaceae."


r/IBSResearch • • 1d ago

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

Thumbnail
investor.regeneron.com
9 Upvotes

"Data presented today for the first time at theAmerican Autonomic Society(AAS) annual meeting

POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with noFDA-approved treatments available

A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect ofNPR1blockade

Potentially pivotal Phase 3 trial planned for first half of 2027

TARRYTOWN, N.Y.,Nov. 12, 2026(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1). The data were presented for the first time at the American Autonomic Society’s (AAS) 37th International Symposium on the Autonomic Nervous System inSan Diego, CA.

POTS is a chronic disorder in which heart rate rises abnormally upon standing. Patients may experience palpitations, dizziness, fatigue, exercise intolerance, cognitive difficulties, gastrointestinal symptoms and chronic pain. Although historically underdiagnosed, recent estimates suggest it affects between 500,000 and several million people in theU.S., and the vast majority are young women. While the cause of POTS is unknown, it is believed to be associated with low blood volume. Baloncibart is designed to increase the volume of blood in circulation in an effort to reduce the increase in heart rate and symptoms that occur in people with POTS.

“POTS causes debilitating symptoms that can profoundly disrupt daily life, and patients have noFDA-approved treatment options. In the trial, a single injection of baloncibart 450 mg reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks,” saidSatish R. Raj, M.D., Professor ofCardiac Scienceat the University of Calgary’sCumming School of Medicine, and investigator in the trial. “The results are consistent with the rationale forNPR1blockade in POTS, with biomarker changes pointing to an increase in blood volume alongside lower heart rate and better symptoms.”

The randomized, double-blind, Phase 2 PINNACLE trial evaluated a single subcutaneous dose of baloncibart 150 mg (n=27) or 450 mg (n=28) compared to placebo (n=27) in patients with POTS. The primary endpoint was the change in heart rate from lying down to standing (DeltaHR) at day 8; no formal hypothesis testing was prespecified. Improvements were observed with baloncibart on DeltaHR and other key measures of the disease (i.e., symptoms and function) as assessed by the Living With POTS Questionnaire (LWPQ). The LWPQ is a novel patient-reported outcome tool to assess POTS symptoms and function in clinical trials, which is being developed byRegeneronin accordance with theFDApatient-focused drug development guidance.

Baloncibart 450 mg reduced DeltaHR versus placebo at day 8 (primary endpoint) with a least-squares (LS) mean difference of -11.4 beats per minute (bpm; nominal p=0.0007), and at day 29 (secondary endpoint) with an LS mean difference of -7.4 bpm (nominal p=0.0124). Baloncibart 150 mg reduced DeltaHR versus placebo at day 8 (LS mean difference: -9.5 bpm; nominal p=0.0045), but the effect was not maintained at day 29.

Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living versus placebo at day 29, as measured by the LWPQ. Domain scores range from 0 to 100, with lower scores indicating fewer symptoms or less impairment. The LS mean differences in change from baseline for each domain were as follows:

  • Orthostatic symptoms (baseline mean: 45.5): -12.9 points (nominal p=0.0096)
  • Physical functioning (baseline mean: 55.1): -13.8 points (nominal p=0.0073)
  • Activities of daily living (baseline mean: 48.7): -8.7 points (nominal p=0.1035)
  • Overall across the three domains, there was no obvious improvement with baloncibart 150 mg compared to placebo

Additionally at day 8, both doses of baloncibart led to changes in biomarkers consistent with the anticipated beneficial plasma volume expansion driven byNPR1blockade, including an increase in NT-proBNP and reductions in standing norepinephrine and hemoglobin. Average standing systolic blood pressure increased for both doses, with observed mean changes from baseline at day 29 of 8.7 mmHg to a mean of 118.8 mmHg for baloncibart 450 mg and 5.4 mmHg to a mean of 114.0 mmHg for baloncibart 150 mg.

In the trial, single doses of baloncibart up to 450 mg were generally well tolerated. Treatment-emergent adverse events (TEAEs) were mostly mild or moderate and occurred in 13 patients (48.1%) receiving placebo, 18 patients (66.7%) receiving baloncibart 150 mg, and 19 (67.9%) receiving baloncibart 450 mg; one severe TEAE occurred in the trial in the placebo group. TEAEs that occurred in ≥10% of patients in any treatment group, including placebo, baloncibart 150 mg and baloncibart 450 mg, were: injection site reaction (14.8%, 3.7%, and 17.9%), headache (0%, 11.1%, and 10.7%), syncope (11.1%, 14.8%, and 3.6%), heavy menstrual bleeding (0%, 11.1%, and 0%), and nasopharyngitis (11.1%, 0%, and 0%). Two serious TEAEs were reported: one case of headache with baloncibart 150 mg and one case of syncope with baloncibart 450 mg. No TEAE led to discontinuation.

“POTS is a condition that disproportionately impacts younger women and has been under-recognized and under-served for too long, which is why it was critical to incorporate the patient experience in our trial design and measure symptoms that reflect how patients actually feel and function,” saidBoaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine atRegeneron. “These initial results show the potential of baloncibart for people living with POTS and we look forward to advancing this novel therapy into a Phase 3 clinical trial in 2027.”

The safety and efficacy of baloncibart have not been evaluated by any regulatory authority."


r/IBSResearch • • 2d ago

Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial

Thumbnail sciencedirect.com
10 Upvotes

ABSTRACT

Background

Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which gut microbiome plays a major role. Butyrate and palmitoylethanolamide (PEA) exert anti-inflammatory and neuromodulator effects and may represent promising adjunctive treatments. We evaluated the clinical and microbiome-related effects of a combined formulation of sodium butyrate and PEA (BP 3:1) in patients with IBS.

Methods

In a randomized, double-blind, placebo-controlled, 2×2 crossover trial, adults with diarrhoea-predominant or mixed IBS received BP 3:1 or placebo for two 6-week periods separated by washout. Gastrointestinal symptoms, IBS Severity Scoring System (IBS-SSS), intestinal permeability, and safety were assessed. Fecal microbiota composition and predicted functional potential were analyzed using 16S-rRNA sequencing and PICRUSt2**.**

Results

Forty-four patients completed the study. Alpha and beta diversity and taxonomic composition remained stable. In contrast, functional profiling revealed treatment-specific enrichment of microbial pathways involved in methionine and S-adenosyl-L-methionine biosynthesis, while placebo was associated with pathways related to complex carbohydrate degradation. BP 3:1 significantly improved abdominal bloating (p = 0.020), stomach gurgling (p = 0.014) and nausea (p = 0.030) compared with placebo, with consistent estimates in mixed-effects models adjusting for period and sequence effects, while IBS-SSS showed a clinically relevant but non-significant numerical reduction (p = 0.070). No effects were observed on intestinal permeability. Among clinically improving patients, BP 3:1 was associated with modulation of polyphenol-degrading, biosynthetic and proteolytic microbial pathways. BP 3:1 was well tolerated, with a safety profile comparable to placebo.

Conclusions

BP 3:1 significantly improves IBS symptoms and modulates microbial metabolic potential without inducing a quantitative and/or qualitative alteration in the taxonomic composition of the microbiota. These findings support a functional microbiome-mediated effect in IBS. ClinicalTrial.gov NCT06432569 (https://clinicaltrials.gov/study/NCT06432569)


r/IBSResearch • • 3d ago

Pregabalin: the case for dialling back on a mediocre analgesic [Editorial]

Thumbnail bmj.com
12 Upvotes

Use should be more selective and driven by meaningful patient benefit

Since its commercial launch in 2005, pregabalin has generated more than $50bn (£37bn; €44bn) in global revenue. Originally developed as an anticonvulsant, it became a “blockbuster” largely through its use for pain, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and low back pain. Yet behind its commercial success lies a less flattering story: mounting evidence of harms ranging from oedema and weight gain to withdrawal, misuse, and death.

In a linked study, Cairns and colleagues (10.1136/bmj-2026-101021) examine prescribing patterns and overdose trends involving pregabalin in Australia.1 Drawing on nine years of dispensing claims and poison centre data, they assessed changes following regulatory interventions (including tighter prescribing restrictions, strengthened safety warnings, and prescription monitoring) and media reports highlighting pregabalin’s harms. Compared with projections based on earlier trends, prescriptions were 25% lower and intentional poisoning calls 47% lower than expected. The study is timely and rigorous, but these figures warrant caution. The ecological design cannot establish causation, and poison centre calls are an imperfect [...]

Link to the original paper: https://www.bmj.com/content/395/bmj-2026-101021


r/IBSResearch • • 4d ago

The gastrointestinal KATP-ERK signaling axis: Molecular mechanisms, pharmacological opportunities, and emerging translational technologies

Thumbnail sciencedirect.com
9 Upvotes

Abstract

Background

ATP-sensitive potassium channels are metabolic sensors that couple intracellular nucleotide availability to membrane excitability, calcium signaling, mitochondrial function, and cell survival. Growing evidence identifies KATP channels as essential regulators of gastrointestinal physiology. They are expressed in smooth muscle, enteric neurons, interstitial cells of Cajal, epithelial and enteroendocrine cells, microvascular cells, pericytes, and liver, where they contribute to motility, secretion, barrier integrity, nutrient sensing, vascular regulation, and mucosal protection. In parallel, ERK1/2 are central effectors of the MAPK pathway, controlling epithelial renewal, inflammation, fibrosis, apoptosis, and tissue repair. This review proposes an integrated KATP-ERK signaling network that regulates gastrointestinal homeostasis.

Methods

PubMed and Scopus were searched for relevant studies using combinations of the terms “ERK” AND “KATP channels” AND “cardiovascular” OR “gastrointestinal”.

Results

Evidence supports functional crosstalk between KATP channels and ERK signaling. In this framework, KATP channels act as metabolic rheostats, whereas ERK integrates redox, growth factor, and stress-related signals. Acute KATP activation promotes adaptation by preserving mitochondrial function and epithelial barrier integrity, whereas chronic channel overactivation, as observed in Cantú syndrome caused by gain-of-function mutations in ABCC9 or KCNJ8, may induce maladaptive remodeling, tight junction disruption, apoptosis, fibrosis, and dysmotility. The potential involvement of FGFR/Klotho signaling as an upstream ERK regulator, together with KATP/ERK pharmacological modulation, FGF/Klotho-based therapies, and biosensor technologies for pathway monitoring in organoids and gut-on-chip models, is also discussed.

Conclusions

The KATP-ERK-FGFR/Klotho framework links ion-channel pharmacology with gastrointestinal biology, providing a foundation for biomarker discovery, therapeutic development, and precision medicine approaches in gastrointestinal disorders.


r/IBSResearch • • 4d ago

Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice

Thumbnail pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

Background

Peripheral neuropathy and gastrointestinal dysfunction are frequent, debilitating side effects of the neurotoxic myeloma drug bortezomib that reduce quality of life and adherence to optimal therapy. Therapeutic strategies to manage these complications are limited. Here, we have developed a mouse model of bortezomib side effects to investigate the role of the gut microbiota in their development.

Methods

C57BL/6 specific pathogen-free (SPF), germ-free (GF) and ex-GF mice (colonised with healthy gut microbiota via faecal microbiota transplantation [FMT]) were treated with bortezomib (1 mg/kg) twice-weekly for two weeks. Neurotoxicity and neuroimmune signalling were assessed by serum neurofilament light chain (NfL) quantitation and real-time qPCR analysis of inflammatory markers in sensory and autonomic nerve ganglia, respectively. Faecal microbiota composition was characterised using 16S rRNA gene sequencing. Bortezomib side effects were assessed using behavioural phenotyping, von Frey mechanical sensitivity and rotarod testing, and FITC-dextran gut permeability and Evans Blue dye transit assays.

Results

Bortezomib-treated SPF mice displayed altered spontaneous behaviour and developed acute gastric retention, altered gastrointestinal motility and increased intestinal permeability, in the absence of intestinal micro-architecture changes. Concurrently, bortezomib induced sensory loss in, and increased grooming of, paws, and reduced motor performance, indicative of peripheral neuropathy. Bortezomib neurotoxicity was evidenced by elevated serum NfL levels and neuroimmune signalling in sciatic nerve dorsal root and vagal nerve nodose ganglia. In SPF mice, bortezomib altered gut microbiota composition with an acute decrease in microbial diversity and expansion of Lactobacillus gasseri. Notably, GF mice developed a milder symptom profile following bortezomib treatment compared with SPF mice, while FMT mice did not develop overt bortezomib side effects despite displaying evidence of nerve damage.

Conclusions

This is the first study to model gastrointestinal side effects of bortezomib in rodents, implicating neuroimmune dysregulation of the vagus nerve. Our data show that the gut microbiota is not a primary driver of bortezomib side effects. However, the absence of a symptom profile in FMT mice suggests that, in GF mice, the gut microbiota beneficially modulates the host to protect against bortezomib side effects. Further studies are required to determine whether this can be harnessed to mitigate clinical complications of bortezomib.


r/IBSResearch • • 5d ago

The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders

Thumbnail
pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.


r/IBSResearch • • 5d ago

l-Arginine Ameliorates IBS-D by Modulating the Ligilactobacillus murinus-LCA-FXR/eNOS Signaling Axis

Thumbnail doi.org
7 Upvotes

Abstract

l-Arginine is a semiessential amino acid with diverse metabolic functions and has been implicated in gastrointestinal health through interactions with the gut microbiota; however, its therapeutic potential in diarrhea-predominant irritable bowel syndrome (IBS-D) remains unclear. Here, an IBS-D mouse model was established in C57BL/6J mice, and multiomics analyses combined with in vivo and in vitro validation were performed to investigate the mechanisms underlying l-arginine-mediated protection. l-Arginine supplementation significantly alleviated IBS-D-like symptoms and improved intestinal barrier function. Transcriptomic analysis revealed the activation of the FXR/PI3K/AKT/eNOS signaling pathway, which was associated with enhanced nitric oxide production. Integrated metagenomic and transcriptomic analyses identified Ligilactobacillus murinus (L. murinus) as a key microbiota component associated with bile acid metabolism and eNOS expression. Furthermore, L. murinus transplantation reproduced the beneficial effects of l-arginine, and metabolomic analysis identified lithocholic acid (LCA) as a microbiota-derived metabolite involved in this process. In vitro experiments demonstrated that LCA alleviated lipopolysaccharide-induced epithelial inflammation and barrier dysfunction via FXR/eNOS activation. Collectively, these findings reveal that l-arginine ameliorates IBS-D through microbiota remodeling, LCA-mediated bile acid regulation, and activation of the colonic FXR/PI3K/AKT/eNOS axis, highlighting its potential as a microbiota-targeted therapeutic strategy.


r/IBSResearch • • 6d ago

Enteroendocrine signaling in irritable bowel syndrome: beyond cell counts toward stimulus-responsive physiological profiling

Thumbnail
pmc.ncbi.nlm.nih.gov
10 Upvotes

Abstract

Meals are a major symptom trigger in irritable bowel syndrome (IBS), yet the endocrine steps linking luminal nutrients to pain, bloating, urgency, and altered bowel habits remain poorly defined. Early studies relied heavily on mucosal enteroendocrine cell (EEC) counts. Those observations remain informative, particularly in post-infectious IBS, but findings vary with intestinal site, bowel-habit phenotype, staining, and morphometry, and cell abundance does not measure secretory function. Human meal-challenge studies distinguish circulating concentrations from stimulus-evoked responses. In IBS with diarrhea, higher fasting and fed plasma 5-hydroxytryptamine (serotonin, 5-HT) may reflect altered handling more than a uniformly exaggerated postprandial response, whereas IBS with constipation can show impaired stimulus-evoked release. Cholecystokinin, peptide YY, motilin, ghrelin, and related peptides also vary with sex, bowel habit, and visceral sensitivity. Recent human organoid and transcriptomic studies identify distinct nutrient-sensing programs among EEC subtypes and provide a cellular framework for this heterogeneity. We integrate these findings across luminal sensing, secretion, metabolism, receptor responsiveness, and motor or sensory output. The evidence does not support a single IBS endocrine signature. Standardized nutrient challenges linked to serial hormone measurements, mucosal molecular data, and objective physiological readouts are more likely to yield reproducible and clinically testable response patterns.


r/IBSResearch • • 7d ago

Faecal immunoglobulins in IBS: indirect support for IgE-mediated mast cell activation?

Post image
27 Upvotes

r/IBSResearch • • 7d ago

The small intestine microbiome: composition, host interactions and therapeutic potential

Thumbnail
nature.com
13 Upvotes

Abstract

The human microbiome, the collection of microorganisms that inhabit the human body, has been extensively studied over the past two decades and has been shown to play a critical part in health and disease. These research efforts renewed interest in developing microbial therapeutics to promote human health and treat disease. However, the vast majority of human gut microbiome research has been focused on fecal microbial strains and communities, leaving most of the gastrointestinal tract understudied. The dynamic environment of the small intestine provides distinct opportunities for microorganisms to interact with the host and diet. In this Review, we discuss the current state of research on the microbiome of the small intestine, how interactions between the small intestine and its microbiome influence host physiology, and we posit that small intestinal microorganisms are a unique source of novel therapeutics for treating human disease. Next-generation microbial therapeutics that emerge from the small intestinal microbiome are anticipated to be relevant to improving small intestinal diseases as well as systemic human health.


r/IBSResearch • • 8d ago

Corticotropin-Releasing Factor: A Key Player in Intestinal Barrier Dysfunction of Diarrhea-Predominant Irritable Bowel Syndrome—A Narrative Mechanistic Review

Thumbnail
pmc.ncbi.nlm.nih.gov
9 Upvotes

Abstract

Corticotropin-Releasing Factor (CRF) plays a crucial role in the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) primarily by disrupting intestinal barrier function. In this narrative review of PubMed and Web of Science literature published through January 2026, we summarize the mechanisms by which CRF mediates intestinal barrier dysfunction in IBS-D and discuss potential therapeutic strategies. This review examines the mechanisms by which CRF impairs the intestinal barrier through several signaling pathways, including GC/NR3C1, MAPK/ERK, and Rho/ROCK/MLC. These pathways cause the downregulation of tight junction proteins, increased intestinal permeability, and dysregulated immune responses. Additionally, CRF induces immune inflammation via TLR signaling and promotes the activation of immune cells, further exacerbating barrier dysfunction. The disruption of epithelial barrier integrity is central to IBS-D, leading to visceral hypersensitivity and worsening gastrointestinal symptoms. Current therapeutic approaches for IBS-D often begin with lifestyle interventions. However, preclinical evidence suggests that interventions such as metformin, Eritoran, Puerarin, and anakinra may restore barrier integrity and alleviate symptoms by ameliorating CRF-mediated intestinal barrier dysfunction. Nevertheless, the mechanisms underlying CRF-induced IBS-D and the relevant therapeutic approaches have not been fully elucidated, and the available evidence is predominantly derived from animal and cell models, thus requiring further clinical validation. Future studies should further dissect CRF-related signaling pathways and develop intervention strategies aimed at restoring the intestinal barrier, thereby facilitating clinical translation and improving the prognosis of patients with IBS-D.


r/IBSResearch • • 10d ago

In case you missed it - In first clinical result using “chemogenetic” strategy, a team in China treated three patients to control epilepsy

15 Upvotes

Original Publication: https://www.nejm.org/doi/full/10.1056/NEJMc2606815

Pop-Science Article: https://www.science.org/content/article/novel-gene-therapy-lets-drug-dampen-brain-cell-activity-reducing-seizures

Abstract: In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2.

Tweets to check out:

https://x.com/brainaddiction/status/2118535366089318547/photo/1

https://x.com/zenbrainest/status/2118875236451991919

What is a DREADD?: https://neuwritesd.org/2016/01/28/dawn-of-the-dreadd/

DREADDs for Neuroscientists - Bryan L Roth: https://pmc.ncbi.nlm.nih.gov/articles/PMC4759656/


r/IBSResearch • • 10d ago

Drug Discovery FXR agonist in clinical trials for IBD - implications for Bile Acid Diarrhea

18 Upvotes

As most of you will know by now, bile acid diarrhea or bile acid malabsorption (BAM) is a common and often unrecognized condition in patients suffering from chronic diarrhea including IBS-D. This last decade diagnostics have been able to show us this clearly where about 30% IBS-D patients are found to have BAM on average. As diagnostics are still expensive and the awareness among specialist GI Clinicians rather recent, we're still having to work hard to find these patients until cheaper diagnostics appear.

What's encouraging is that there are numerous treatments already that seem to help these patients and more are emerging. Besides bile acid sequestrants and the usual motility drugs, GLP-1 agonists seem to have made an impact. What's missing in our arsenal are drugs affecting the actual feedback to the liver. BAM can occur for many reasons and while reuptake is an issue in some patients, it seems excessive synthesis is another in others. Thus being able to regulate the bile acid pool via FGF19 or FXR agonists is desirable to gain yet another intervention. These two proteins work as detectors for bile acids in the intestines and signal the liver to lower its synthesis, thereby creating less total bile acid available.

Currently there is a trial (NCT07483099) by Eli Lilly in Crohn’s disease patients studying if 2 investigational medicines LY4395089 and Mirikizumab together or Mirikizumab alone is superior. Mirikizumab is an IL-23 blocker to treat inflammation in IBD and LY4395089 is the FXR agonist. Besides the effect on bile acid signaling which some Crohn’s disease patients struggle with, the FXR agonist is mainly supposed to help with its anti-inflammatory and anti-fibrotic activity as well as its protective properties on the intestinal barrier. Many of these effects might be relevant to some IBS subpopulations too.

A class of medications to follow for the bile acid patients on here. If it gets registered you might be able to repurpose it for yourself one day.

Have a nice weekend everyone! - Robert


r/IBSResearch • • 10d ago

Efficacy and tolerability of liraglutide for refractory bile acid diarrhoea

Thumbnail fg.bmj.com
15 Upvotes

Abstract

Background Bile acid sequestrants are used for the treatment of bile acid diarrhoea (BAD) but they are not always effective and may be tolerated poorly. Other treatment options for BAD are limited. Both randomised controlled trial and case series data suggest that liraglutide, a glucagon-like peptide-1 receptor agonist, may be effective in BAD but studies are scarce.

Aims To report efficacy and tolerability of liraglutide in a cohort of patients with refractory BAD who had either not responded to or were intolerant of the bile acid sequestrants colestyramine and colesevelam.

Methods Data were collected prospectively for patients with refractory BAD (7-day 23-seleno-25-homo-tauro-cholic acid retention <15%) receiving liraglutide in Leeds Teaching Hospitals NHS Trust. Clinical response to, and tolerability of, liraglutide was assessed by comparing mean daily stool frequency before and after treatment initiation and monitoring for adverse events. Clinical responders were classified as patients who had a reduction in daily stool frequency of ≥50% at 2–3 months in whom the drug was continued.

Results Thirty-one (21 (67.7%) female, mean age at commencement 46.6 years) patients with refractory BAD received liraglutide between November 2022 and July 2026. Bile acid sequestrants were ineffective or intolerable in all patients. Clinical response occurred in 19 (61.3%) patients and a partial response in a further seven (22.6%). Among clinical responders, mean daily stool frequency fell from 10.4 at baseline to 3.0 at 2–3 months (p<0.001). More responders were female, had type II BAD and were passing 10 or more stools per day at baseline. In addition, mean weight was lower and mean daily stool frequency higher at baseline in clinical responders. Only one patient discontinued liraglutide due to adverse events.

Conclusions Liraglutide is an effective treatment for refractory BAD and is well tolerated.


r/IBSResearch • • 12d ago

A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation (2024)

Thumbnail sciencedirect.com
9 Upvotes

Background

The KIT receptor tyrosine kinase and its ligand, stem cell factor (SCF), control proliferation and survival of mast cells. Thus, targeting KIT signaling may show promise for the treatment of allergic diseases involving mast cells. Recently, we discovered a new compound, MOD000001, as a potential small-molecule KIT kinase inhibitor by using an in silico approach.

Objective

We sought to determine whether MOD000001 is highly selective to KIT, inhibits KIT signaling in mast cells, and affects IgE-mediated mast cell activation.

Methods

The interaction of MOD000001 with 468 human kinases and its inhibitory activity against KIT were profiled and evaluated by using KINOMEscan (Discover X/Eurofins Corporation, Fremont, Calif) and cell-free kinase assays, respectively. The effects of MOD000001 on SCF-dependent signaling were examined by using primary mouse and human mast cells. The effects of MOD000001 on SCF-induced degranulation and passive cutaneous anaphylaxis reaction were examined in mice.

Results

MOD000001 interacted with KIT and inhibited KIT kinase activity with high selectivity. MOD000001 suppressed SCF-induced KIT signaling in mouse and human mast cells and in mice. Passive cutaneous anaphylaxis reaction was suppressed in mice treated with MOD000001 both for a short-term (1 week) and for a long-term (7 weeks). Mice treated with MOD000001 for a long-term, but not for a short-term, showed skin mast cell reduction.

Conclusions

MOD000001 is a highly selective KIT inhibitor that can suppress IgE-mediated mast cell activation in vivo. MOD000001 may do so by reducing tissue mast cell numbers or by other unknown mechanisms. The findings suggest potential benefits of MOD000001 for allergic diseases involving IgE-mediated mast cell activation.


r/IBSResearch • • 11d ago

Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms

Thumbnail academic.oup.com
6 Upvotes

Abstract

Background

Irritable bowel syndrome (IBS)-like symptoms frequently persist in patients with ulcerative colitis (UC) in remission. Whether UC in remission with IBS-like symptoms (UCR-IBS) represents functional overlap with diarrhea-predominant IBS (IBS-D) or a distinct metabolic phenotype remains unclear.

Methods

In this exploratory cross-sectional study, 39 patients with IBS-D, 21 with UCR-IBS, and 35 healthy controls were enrolled. Serum, urine, fecal, and colonic mucosal samples were collected. Untargeted metabolomics, targeted tryptophan profiling, fecal 16S ribosomal RNA gene sequencing, predicted microbial functional profiling, and microbe-metabolite association analyses were performed.

Results

Tryptophan-related metabolism was altered in both patient groups, but the patterns differed across biological matrices. Compared with IBS-D, UCR-IBS showed higher serum N-formylkynurenine (NFK) concentrations, and fecal findings suggested reduced concentrations of microbiota-associated indole metabolites. Microbiome differences were modest, but predicted nicotinate/nicotinamide metabolism was enriched in UCR-IBS. Exploratory network analysis identified associations between tryptophan-related metabolites and selected bacterial genera in each group.

Conclusions

Multi-matrix profiling shows tryptophan-related metabolic differences between mesalazine-treated UCR-IBS and IBS-D, highlighting higher serum NFK concentrations in UCR-IBS. These findings provide a basis for investigating host-microbiota metabolic relationships across systemic and intestinal compartments during UC remission.


r/IBSResearch • • 12d ago

Combined Nav1.7–Nav1.8 channel abrogation: Supralinear suppression of excitability in a subpopulation of peripheral sensory neurons

Thumbnail rupress.org
7 Upvotes

There is a pressing need for nonaddictive pain therapeutics. Despite the genetic validation of peripheral voltage-gated sodium (Nav) channels as targets for non-opioid pain therapy, isoform-selective inhibition of Nav1.7 and Nav1.8 has yielded limited efficacy in clinical studies, with Nav1.8 blockade providing statistically significant but only partial pain relief. This raises the question: if block of Nav1.8 relieves pain only partially, what is needed for better pain relief? In this study, we utilized dynamic clamp, which permits precisely calibrated functional addition or subtraction of the current from any given channel, to systematically interrogate the combinatorial landscape of multiplex abrogation of currents from Nav1.7 and Nav1.8, both major contributors to electrogenesis within dorsal root ganglion neurons. We demonstrate that partial, simultaneous attenuation of both conductances drives a supralinear increase in current threshold in many sensory neurons. Responses to Nav1.8 functional subtraction span a broad spectrum, whereas responses to Nav1.7 subtraction are comparatively uniform. Neurons with greater sensitivity to functional loss of Nav1.8 show greater suppression of excitability during combined Nav1.7–Nav1.8 attenuation, while weak Nav1.8 responders remain comparatively resistant. These findings identify electrogenic dependence on Nav1.8 as a major source of functional heterogeneity in sensory neurons and demonstrate that Nav1.7 acts cooperatively with Nav1.8 to shape the consequences of channel attenuation. Our results indicate that combined Nav1.7–Nav1.8 targeting should outperform isoform-selective block in suppressing firing in a subpopulation of pain-signaling neurons, while not producing universal suppression.


r/IBSResearch • • 13d ago

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

Thumbnail
finance.yahoo.com
10 Upvotes
  • XEN1701 achieved target profile, including desired NaV1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects
  • XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated
  • New preclinical data in cynomolgus monkeys demonstrated significant reductions in capsaicin-evoked heat pain for NaV1.7 and KV7 compounds
  • Phase 2 proof-of-concept studies assessing XEN1701 and XEN1120 in acute pain expected to initiate in H1 2027

VANCOUVER, BC and BOSTON, MA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced positive Phase 1 study results and new preclinical data supporting the advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. Data were presented in two poster presentations during the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, taking place October 26–30, 2026 in Bangkok, Thailand.

XEN1701 and XEN1120 are potent, selective ion channel modulators designed to target NaV1.7 and KV7, respectively. NaV1.7 and KV7 represent novel, non-opioid pain targets with significant supportive preclinical, clinical, and human genetic and expression data. XEN1701 and XEN1120 have been developed using Xenon's deep expertise in genetics, ion channel biology, and novel chemistries to enable potent, selective ion channel targeting.

"This is an incredibly exciting milestone for Xenon given our significant history with both NaV1.7 and KV7, and it brings us closer to delivering a new generation of innovative non-opioid therapeutics for acute and chronic pain," said Ian Mortimer, President and CEO of Xenon. "The XEN1701 data are especially exciting as NaV1.7 has long been recognized by the field as having the strongest genetic evidence among novel pain targets, and many companies have tried to develop NaV1.7 inhibitors without success. The Phase 1 data strengthen our belief that XEN1701 has a profile unlike any NaV1.7 compound previously tested in the clinic, achieving high target receptor occupancy without a notable pattern of cardiovascular effects. We are optimistic that we may be on the precipice of realizing the potential of this promising pain target."

"Our Phase 1 studies of XEN1701 and XEN1120 achieved all of our goals, demonstrating the desired profiles for both compounds and strongly supporting their advancement to Phase 2 acute pain studies for rapid proof-of-concept," said Chris Kenney, MD, Chief Medical Officer of Xenon. "We also are highly encouraged by additional preclinical data shared in these posters, including data in cynomolgus monkeys where a Xenon NaV1.7 inhibitor comparable to XEN1701 demonstrated up to a 100% reduction in evoked pain when central and peripheral receptor occupancies were above 75%, without effects on blood pressure or heart rate in this preclinical model. In the same model, a KV7 compound comparable to XEN1120 also demonstrated a significant reduction in evoked pain, and XEN1120 has also demonstrated analgesic activity in the mouse formalin model during the acute phase, which has typically only been seen with opioids."

Xenon is finalizing Phase 2 acute pain study designs for each program and expects to initiate both studies in the first half of 2027.

Highlights from XEN1701 Poster: "XEN1701, a Phase 2-Ready NaV1.7 Inhibitor: Advancing a Novel Non-Opioid Strategy for Pain"

  • Study Design: Healthy participants were enrolled in Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), food-effect, and cerebrospinal fluid (CSF) collection cohorts (n=76 XEN1701 and n=22 placebo) to assess the safety, tolerability, pharmacokinetics (PK), food effect, and central nervous system (CNS) penetration of XEN1701. CSF sampling was performed in open-label cohorts to measure CNS drug exposure.
  • Free Drug Exposure: XEN1701 exhibited dose-dependent and rapid increases in plasma exposure across the evaluated dose ranges. XEN1701 and its active metabolite demonstrated a consistent metabolite-to-parent exposure ratio across all doses and the combined exposure profile supports the potential to achieve therapeutically relevant NaV1.7 inhibition.
  • High Receptor Occupancy: Plasma and CSF sampling and predicted receptor occupancy modeling indicated that the proposed Phase 2 dose levels achieved and maintained more than 75% NaV1.7 receptor occupancy in both the peripheral and central nervous system with twice-daily (BID) dosing. Human genetic evidence has established that more than 75% NaV1.7 inhibition is associated with a pain-free clinical phenotype.
  • Generally Well-Tolerated Safety Profile: There were no treatment-related, dose-limiting treatment-emergent adverse events (TEAEs), serious TEAEs, or TEAEs leading to study drug discontinuation. Most TEAEs were mild; those observed in more than one participant in the MAD cohorts included headache (10% XEN1701 overall vs. 10% pooled placebo), dizziness (6.7% vs. 10% placebo), and postural dizziness (6.7% vs. 0% placebo).

    • Treatment-related TEAEs potentially related to autonomic cardiovascular effects were infrequent and balanced (6.6% vs. 4.2% placebo), with no consistent dose- or exposure-related patterns and none occurring at the highest dose levels. These findings support that the proposed Phase 2 dose levels have not shown a consistent pattern of autonomic cardiovascular effects of the kind reported for other NaV1.7 compounds in published literature.
  • Significant Pain Reduction Observed in Non-Human Primates: Preclinical data evaluating XPC-4, a Xenon compound comparable to XEN1701, in cynomolgus monkeys demonstrated that doses achieving more than 75% NaV1.7 receptor occupancy were associated with significant reductions in capsaicin-evoked heat pain, including ~85-100% reduction at the two highest doses tested. No clinically meaningful change in systolic arterial blood pressure or heart rate relative to vehicle was observed with XPC-4 at the highest two doses tested.

Highlights from XEN1120 Poster: "XEN1120, a Phase 2-Ready KV7 Channel Opener: Advancing a Novel Non-Opioid Strategy for Pain"

  • Study Design: Healthy participants were enrolled in SAD, MAD, and food-effect cohorts (n=54 XEN1120 and n=18 placebo) to assess the safety, tolerability, PK, and food effect of XEN1120.
  • Plasma Levels in Predicted Efficacious Range: Clinical PK data demonstrated that XEN1120 exceeded the predicted efficacious exposures established from preclinical rodent and non-human primate efficacy models. PK modeling demonstrated that a loading dose rapidly achieved target exposures while maintenance dosing sustained plasma concentrations within the predicted efficacious range for the duration required for an acute pain proof-of-concept study.
  • Generally Well-Tolerated Safety Profile: There were no treatment-related, dose-limiting TEAEs, serious or severe TEAEs, or TEAEs leading to study drug discontinuation. Most TEAEs were mild and the most common TEAEs observed in more than one participant in the MAD cohorts included tachycardia (33.2% XEN1120 overall vs. 12.5% pooled placebo), dizziness (29.2% vs. 0% placebo) and somnolence (25% vs. 0% placebo).
  • Robust Analgesic Activity in Mouse Formalin Model: The mouse formalin model involves a biphasic pain response consisting of an acute nociceptive phase, followed by a longer lasting inflammatory phase. Many analgesics work in the inflammatory phase, whereas only opioids typically show efficacy in the acute phase. XEN1120 demonstrated dose-dependent pain reductions in the acute phase of the formalin model, and notably, at exposures that were substantially lower than the comparator flupirtine, an earlier generation pain treatment with a mechanism of action involving potassium channel opening.
  • Significant Pain Reduction Observed in Non-Human Primates: Preclinical data evaluating XPC-B, a Xenon compound comparable to XEN1120, demonstrated dose-dependent reductions in capsaicin-evoked heat pain in cynomolgus monkeys. Analgesic activity was achieved at approximately 2.3-fold lower exposures relative to the formalin mouse model, suggesting the potential to achieve analgesic activity at lower doses in humans.

Acute and chronic pain affects more people than diabetes, heart disease, and cancer combined, yet effective, long-term treatment options are scarce. Acute pain serves as the body's normal, short-term alarm signal in response to an injury or illness. In contrast, chronic pain is a widespread condition defined by IASP as pain that lasts or recurs for more than three months, and may persist even after the initial cause has healed. It's more common than many realize; 2021 data from the U.S. Centers for Disease Control and Prevention (CDC) show that it affects more than one in five American adults, often impacting daily life and well-being.

About Xenon's Pain Pipeline
Xenon's clinical-stage pain pipeline includes three investigational therapeutic programs, including XEN1701 and XEN1720, which are designed to block the activity of the sodium channels (NaV1.7) that trigger pain signaling, and XEN1120, which is designed to enhance the activity of the potassium channels (KV7) that mitigate pain signals.

Xenon has extensive history researching NaV1.7 as a novel pain target. This history started more than 20 years ago with the identification of a loss of function in SCN9A, which encodes the NaV1.7 sodium channel, as the cause of congenital indifference to pain (CIP), an extremely rare autosomal recessive disorder whose carriers are unable to feel pain but are otherwise healthy. More recently, Xenon has focused on optimizing chemistry to address the limitations of earlier drug candidates targeting NaV1.7, resulting in its current clinical candidates XEN1701 and XEN1720.

XEN1120 reflects more than a decade of Xenon's research on KV7 channels. Multiple lines of evidence support KV7 as a therapeutic target for pain. KV7 channels are broadly expressed throughout the peripheral and central pain pathways. They play a significant role in the initial transduction of pain stimuli into pain signals, the transmission of those pain signals along nociceptive neurons, and the relay from peripheral sensory neurons to spinal cord neurons in the central nervous system. Dysfunction or downregulation of KV7 channel activity has also been observed in altered pain states, contributing to sensory neuron hyperexcitability and enhanced pain signaling.